Therefore, in the present pilot study, we investigated these alterations by measuring the expression of FOXO1 and FOXO3A in combination with two inflammatory genes interleukin 1β (IL-1β) and IL-6 in patients with diabetes type II, obesity, depression, and NDs, and compared them with normal individuals. This evidence concerns the gene FOXO1 and depressive disorder.